Rocket Pharma stock price target raised to $33 vs. $30 at Chardan

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY. (See Full Profile)

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply